Baxter International Inc. (BAX) Upgraded by Zacks Investment Research to Buy

Cornelia Mascio
Ottobre 21, 2017

14-day Williams %R for Baxter International Inc. Royal Bank Of Canada reiterated a "hold" rating and issued a $60.00 target price on shares of Baxter International in a research report on Friday, September 1st. The brokerage now has $69.00 target price on the medical instruments supplier's stock.

In terms of performance, shares of Electronic Arts Inc. Of the major positives, a favorable product mix, stringent cost control and expanding operating margin are notable. Clarivest Asset Mngmt Ltd Limited Liability Company reported 97 shares. The company recently completed the acquisition of Claris Injectables.

On July 11 the stock rating was upgraded from "Market Perform" to "Outperform" by analysts at BMO Capital. They noted that the move was a valuation call. During the past six months, Baxter International Inc. On Friday, July 28 the stock rating was maintained by UBS with "Neutral". Baxter International had 39 analyst reports since July 30, 2015 according to SRatingsIntel. July 25 investment analysts at Morgan Stanley left the company rating at "Equal-Weight" and moved down the price target from $75.00 to $55.00. Baxter International presently has an average rating of "Buy" and a consensus target price of $65.69. Citigroup starting coverage on BAX with a rating of "Neutral". 562,142 shares of the company's stock were exchanged. Using a scale from 0 to 100, a lower score would represent an undervalued company and a higher score would indicate an expensive or overvalued company.

Baxter International Inc.'s P/E ratio is 38.51 and the market value is 34.58B. Gemmer Asset Limited Liability Corporation stated it has 0% in Baxter International Inc (NYSE:BAX). The dividend payment was $0.160 per share for the quarter which is $0.64 annualized. The average estimate of Wall Street analysts had projected 0.57. They expect $0.59 earnings per share, up 5.36 % or $0.03 from last year's $0.56 per share. As of the last earnings report the EPS was $1.65 and is expected to be $2.39 for the current year with 544,870,000 shares outstanding.

COPYRIGHT VIOLATION NOTICE: This report was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of US & worldwide copyright and trademark legislation. Baxter International Inc (NYSE:BAX) has risen 32.55% since October 20, 2016 and is uptrending.

In other Baxter International news, Director Carole J. Shapazian sold 4,020 shares of the company's stock in a transaction dated Thursday, August 24th.

If the value is greater than one, the 50 day moving average is above the 200 day moving average, which may signal positive stock price momentum. Following the completion of the transaction, the director now owns 13,868 shares in the company, valued at approximately $854,407.48. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Giuseppe Accogli sold 12,670 shares of the stock in a transaction that occurred on Thursday, August 17th. (NASDAQ:EA) shares have been seen trading -3.53% away from the 20-day moving average. The company had revenue of $2.61 billion during the quarter, compared to analyst estimates of $2.59 billion. The disclosure for this sale can be found here. Following volatility data can help measure how much the stock price has fluctuated over the specified time period. The stock declined 0.06% or $0.04 reaching $62.46 on the news.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company.

As of now, the increased share price of Baxter International Inc. makes it a lucrative buy for investors. About 3,302 shares traded. Insiders have sold 35,050 shares of company stock valued at $2,158,587 in the last 90 days. Acrospire Investment Management LLC boosted its stake in Baxter International by 71.3% in the second quarter. As of quarter end Nisa Investment Advisors, LLC had acquired 275 shares growing its position 0.2%. Harvest Fund Management Co. It also upped Mondelez International Inc (NASDAQ:MDLZ) stake by 98,244 shares and now owns 100,092 shares. Ltd now owns 2,928 shares of the medical instruments supplier's stock valued at $177,000 after acquiring an additional 226 shares in the last quarter. Investors can use these support and resistance levels to refine their entries and exits from stocks.

Quantitative Systematic Strategies LLC decreased its position in Baxter International Inc. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE